Shares of Emcure Prescription drugs Ltd soared 7% on Monday, 10 November, after the corporate introduced that they’ve fashioned a strategic alliance with Novo Nordisk India to develop Poviztra®, the second model of Wegovy® (semaglutide injectable 2.4 mg), as a part of its efforts to extend entry to its globally recognised anti-obesity drugs.
Emcure turns into the primary Indian pharmaceutical enterprise to have unique distribution and commercialisation rights for semaglutide for persistent weight administration in India because of the transaction.
Beneath the settlement, Emcure will deal with the commercialisation, advertising, and distribution of Poviztra®, increasing Novo Nordisk’s presence to achieve extra pharmacies and sufferers, significantly in smaller cities and areas past the multinational’s present attain.
Poviztra® shall be a second model of Wegovy®, which Novo Nordisk launched in India in June 2025. Each formulations include semaglutide 2.4 mg, a once-weekly GLP-1 receptor agonist that controls urge for food and calorie consumption, leading to appreciable and sustained weight reduction.
In international medical research performed underneath Novo Nordisk’s STEP and SELECT programmes, one in each three folks on semaglutide misplaced greater than 20% of their weight. The chemical has additionally been proven to scale back the chance of main cardiovascular occasions amongst chubby and overweight adults.
Poviztra®’s launch intends to supply steady entry and elevated availability of semaglutide-based remedy in India, the place medical therapy of weight problems remains to be in its early phases.
Novo Nordisk’s Senior Vice President, Area APAC, Jay Thyagarajan, mentioned the settlement demonstrates the corporate’s dedication to extending weight problems care in India.
“Weight problems is a critical persistent illness affecting hundreds of thousands of individuals throughout India. Recognising this problem, we launched Wegovy® earlier this 12 months. Now, by becoming a member of palms with Emcure Pharma, we are able to broaden entry to protected, efficient, and high-quality weight problems therapy,” he mentioned.
Thyagarajan went on to say that the cooperation combines Novo Nordisk’s scientific management in GLP-1 medicines with Emcure’s sturdy advertising and distribution community to broaden therapy entry throughout India.
Emcure Prescription drugs’ CEO and Managing Director, Satish Mehta, acknowledged that the enterprise is thrilled to introduce the world’s most trusted GLP-1-based weight-loss chemical to Indian sufferers.
“With our deep understanding of India’s various geography and powerful presence throughout therapeutic segments, we’re assured of constructing Poviztra® accessible to sufferers who want it most,” Mehta mentioned.
Emcure’s sturdy area pressure and established retail connections are meant to assist broaden entry exterior metropolitan areas, reaching Tier II and Tier III cities the place weight problems administration is at the moment underserved.
At 3:02 pm, the shares of Emcure Pharma had been buying and selling 5.10% larger at Rs 1,431.90 on NSE.
Uninterested in lacking scorching shares? Unicorn Indicators offers highly effective instruments like inventory scans and extra assist you to make knowledgeable buying and selling selections. Obtain now and take management of your portfolio!
